Esperion Therapeutics, Inc.ESPREarnings & Financial Report
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Revenue
$69.1M
Gross Profit
N/A
Operating Profit
$-4.4M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
-6.4%
Net Margin
N/A
YoY Growth
114.3%
EPS
$-0.14
Esperion Therapeutics, Inc. Q4 FY2024 Financial Summary
Esperion Therapeutics, Inc. reported revenue of $69.1M (up 114.3% YoY) for Q4 FY2024, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $69.1M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | -6.4% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Esperion Therapeutics, Inc. Q4 FY2024 revenue of $69.1M breaks down across 2 segments, led by Collaboration Revenue at $37.6M (54.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaboration Revenue | $37.6M | 54.3% |
| Products | $31.6M | 45.7% |
Esperion Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Esperion Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Collaboration Revenue and Products) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Collaboration Revenue | $124.7M | $46.6M | $42.1M | $30.1M |
| Products | $43.7M | $40.7M | — | $34.9M |
Esperion Therapeutics, Inc. Annual Revenue by Year
Esperion Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $403.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $403.1M |
| 2024 | $332.3M |
| 2023 | $116.3M |
Esperion Therapeutics, Inc. Quarterly Revenue & Net Profit History
Esperion Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $168.4M | +143.7% | N/A | N/A |
| Q3 FY2025 | $87.3M | +69.1% | $-31.3M | -35.9% |
| Q2 FY2025 | $82.4M | +11.6% | $-12.7M | -15.4% |
| Q1 FY2025 | $65.0M | -52.8% | $-40.5M | -62.2% |
| Q4 FY2024 | $69.1M | +114.3% | N/A | N/A |
| Q3 FY2024 | $51.6M | +52.0% | $-29.5M | -57.2% |
| Q2 FY2024 | $73.8M | +186.3% | $-61.9M | -83.9% |
| Q1 FY2024 | $137.7M | +466.1% | $61.0M | 44.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $137.7M | $73.8M | $51.6M | $69.1M | $65.0M | $82.4M | $87.3M | $168.4M |
| YoY Growth | 466.1% | 186.3% | 52.0% | 114.3% | -52.8% | 11.6% | 69.1% | 143.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $373.1M | $352.3M | $314.1M | $343.8M | $324.0M | $347.1M | $364.0M | $465.9M |
| Liabilities | $667.4M | $696.5M | $684.3M | $732.5M | $750.2M | $780.6M | $815.4M | $767.9M |
| Equity | $-294.3M | $-344.2M | $-370.2M | $-388.7M | $-426.2M | $-433.5M | $-451.4M | $-302.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $53.8M | $-7.2M | $-35.3M | $-35.0M | $-22.6M | $-31.4M | $-4.3M | $45.2M |